How Long Will You — Stay on Sorafenib?

Your team will arrange a first assessment scan after a number of weeks of treatment — the exact timing depends on your cancer type and your team's protocol. That scan gives the first objective picture of whether the drug is holding the cancer stable. Do not assume it is not working before that scan happens. Symptoms do not reliably track what a scan will show, and many people feel no different in the early weeks regardless of whether the drug is working.

When a scan shows disease progression, your oncologist will discuss what comes next. For some cancer types there are further targeted therapies or other systemic treatments to consider. For others, the conversation will turn to clinical trials or to treatment aimed at managing symptoms rather than controlling the cancer. The right next step depends on your cancer type, your general fitness, and what options are available. Progression on sorafenib is not the end of treatment options — it is the point at which the plan changes.

Planned breaks are not part of the standard approach because sorafenib works by maintaining a continuous level of the drug in your system. Stopping it gives the cancer an opportunity to grow. If side effects are pushing you toward wanting a break, the right conversation is with your oncology team about a dose reduction or a short interruption with a clear plan to restart. Do not stop taking sorafenib without telling your team first.

You continue for as long as the disease stays stable and side effects remain manageable. Stable disease on repeated scans is the outcome sorafenib aims to produce, not an intermediate result before something better. There is no point at which your team says the cancer has been stable long enough to stop. If you find the indefinite nature of this difficult — many people do — that is worth raising directly with your oncologist, not just accepting quietly.

Sometimes, yes. If sorafenib was stopped because of a side effect that has since resolved, your oncologist may consider restarting at a lower dose, depending on how serious the reaction was. If it was stopped because of disease progression, restarting the same drug is not usually the approach — the focus shifts to what comes next. The decision is made case by case and depends on why it was stopped, your current health, and what alternatives are available.

Progression means the cancer has grown or spread since the last scan. Reports use terms like 'interval increase in size' or 'new lesion'. Your oncologist will interpret the report and tell you in plain terms what it means for the treatment plan. A small change on one scan does not always trigger an immediate decision — your team may confirm it on a follow-up scan before concluding that sorafenib has stopped working. Ask your oncologist what the report showed and what their interpretation is, rather than reading it alone.